SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy

por Selim, Rania, Wellens, Judith, Marlow, Luke, Satsangi, Jack J
Publicado 2021

Decrease in uptake of SARS-CoV-2 vaccine in patients with inflammatory bowel disease on intravenous biological therapy

por Selim, Rania, Wellens, Judith, Brann, Stephanie, Marlow, Luke, Adams, Alex, Satsangi, Jack J
Publicado 2022

Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease

por Wellens, Judith, Brann, Stephanie, Adams, Alex, Marlow, Luke, Lindsay, James O, Satsangi, Jack J
Publicado 2022

1163: BOTH VEDOLIZUMAB AND ANTI-TNF THERAPY ARE ASSOCIATED WITH ATTENUATION OF SEROLOGICAL AND NEUTRALIZING RESPONSES TO SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE

por Wellens, Judith, Edmans, Matthew, Obolski, Uri, Marlow, Luke, Brann, Stephanie, Dunachie, Susanna, Eyre, David W., Helmus, Drew, Barnes, Eleanor, Colombel, Jean Frederic, Wong, Serre-Yu, Klenerman, Paul, Lindsay, James O., Thompson, Craig, Satsangi, Jack J.
Publicado 2022